BiotechTube
Biosceptre

Biosceptre

Cambridge, United Kingdom· Est.
biosceptre.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.3M

Overview

Biosceptre is pioneering a multi-targeted universal CAR T-cell therapy platform, BRiDGECAR™, centered on the novel oncology target nfP2X7. With Nobel prize-winning scientific leadership and foundational research from the University of Sydney, the company is advancing a pipeline intended to address numerous malignancies. Recently securing £8.1 million in funding, Biosceptre is positioned to accelerate its innovative programs, though it remains a preclinical-stage, pre-revenue entity facing significant development and competitive risks.

Oncology

Technology Platform

BRiDGECAR™ system: a universal CAR T-cell therapy platform targeting the nfP2X7 antigen, combined with multiple targeted antibodies for a multi-targeted approach to treating a wide range of cancers.

Funding History

2
Total raised:$1.3M
Grant$800K
Grant$500K

Opportunities

The BRiDGECAR™ platform addresses the massive unmet need for effective CAR-T therapies in solid tumors and offers a potential universal, off-the-shelf solution that could dramatically improve manufacturing scalability and patient access.
Successful development could position the company as a leader in next-generation, broad-spectrum oncology cell therapy.

Risk Factors

The company faces high technical risk as its novel nfP2X7 target and complex universal CAR-T platform are unproven in humans.
As a preclinical, pre-revenue entity, it is heavily dependent on raising significant additional capital in a competitive financing environment to advance through costly clinical development.

Competitive Landscape

Biosceptre operates in the highly competitive field of next-generation CAR-T and allogeneic cell therapies, competing against large pharmaceutical companies and well-funded biotechs developing their own platforms for solid tumors. Its differentiation hinges on the unique nfP2X7 target and its multi-targeted antibody combination approach.

More companies in Oncology (General) →More companies in United Kingdom →